Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

NCT04547946 · clinicaltrials.gov ↗

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: dabrafenib + trametinib

Sponsor

Novartis Pharmaceuticals